Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606901 | 1.00 | ACHE (0.62) | ACHEDRD2DRD3CHRNA7KDM1A | |
| SCHEMBL1237849 | 1.00 | ACHE (0.62) | ACHEDRD2DRD3CHRNA7KDM1A | |
| SCHEMBL30402024 | 1.00 | ACHE (0.62) | ACHEDRD2DRD3CHRNA7KDM1A | |
| Hydrochloric Acid SCHEMBL2688145 | 0.98 | ACHE (0.60) | ACHEDRD2DRD3CHRNA7KDM1A | |
| SCHEMBL30563659 | 0.90 | ACHE (0.60) | ACHEDRD2DRD3HTR2AHTR2C | |
| SCHEMBL2463469 | 0.90 | ACHE (0.60) | ACHEDRD2DRD3HTR2AHTR2C | |
| SCHEMBL4418237 | 0.90 | ACHE (0.60) | ACHEDRD2DRD3HTR2AHTR2C | |
| SCHEMBL269087 | 0.90 | ACHE (0.60) | ACHEDRD2DRD3HTR2AHTR2C | |
| SCHEMBL30563644 | 0.90 | ACHE (0.60) | ACHEDRD2DRD3HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL5969966 | 0.88 | ACHE (0.62) | ACHEDRD2DRD3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2024-03-19 | — | — | US | disclosed |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CHU NANTES (FR) | 2021-01-14 | — | — | US | disclosed |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CHU NANTES (FR) | 2021-01-14 | — | — | US | disclosed |
| EP-3630759-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | Centre National De La Recherche Scientifique (FR) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215557-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-11-29 | — | — | WO | disclosed |
| EP-2185525-B1 | PYRAZOLE 3,5 CARBOXYLATE DERIVATIVES PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2016-12-14 | — | — | EP | disclosed |
| EP-2844643-B1 | PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2844643-B1 | PYRIMIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9199946-B2 | Pyrimidinone carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| WO-1998047877-A1 | 2-BENZOYL-1,2,3,4-TETRAHYDROISOQUINOLINE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HEPATIC PRODUCTION OF APOB-100 | GLAXO GROUP LIMITED (GB) | 1998-10-29 | — | — | WO | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| US-5246915-A | Herbicides | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-09-21 | — | — | US | disclosed |
| EP-0207563-B1 | A METHOD FOR CONTROLLING WEEDS | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-07-31 | — | — | EP | disclosed |
| EP-0179667-B1 | N6-SUBSTITUTED ADENOSINES | WARNER-LAMBERT COMPANY (US) | 1989-12-27 | — | — | EP | disclosed |
| US-4791103-A | HYPOTENSIVE AGENTS, PSYCHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| US-4684398-A | Herbicidal cyanoguanidines and cyanoisothioureas | THE DOW CHEMICAL COMPANY (US) | 1987-08-04 | — | — | US | disclosed |
| EP-0207563-A2 | A method for controlling weeds | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-01-07 | — | — | EP | disclosed |
| EP-0179667-A2 | N6-substituted adenosines | WARNER-LAMBERT COMPANY (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CACNA1E, KCNA1, KCNT1 | ACHE 3887/4885DRD2 3800/4885DRD3 3747/4885 |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CACNA1E, KCNA1, KCNT1 | ACHE 3887/4885DRD2 3800/4885DRD3 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.